Chardan Raises Price Target on Dyne Therapeutics to $31 From $20 on Increased Confidence in Lead Assets for DM1, DMD, Keeps Buy Rating
Chardan Raises Price Target on Dyne Therapeutics to $31 From $20 on Increased Confidence in Lead Assets for DM1, DMD, Keeps Buy Rating
Chardan將Dyne Therapeutics的目標股價從20美元上調至31美元，原因是對DM1、DMD的主要資產的信心增強，維持買入評級
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊